Dawn of a new therapeutic era for spinal muscular atrophy

The Lancet

Volumn 388, Issue 10063, 2016, Pages 2964-2965

  Gillingwater, Thomas H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NUSINERSEN; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2;

HUMAN; MOTONEURON; MOTOR PERFORMANCE; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL MUSCULAR ATROPHY;

HUMANS; MUSCULAR ATROPHY, SPINAL;

EID: 85006276883     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32390-X     Document Type: Note

References (12)

1. 1 Lefebvre, S, Bürglen, L, Reboullet, S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80 (1995), 155–165.
2. 2 Finkel, RS, Chiriboga, CA, Vajsar, J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label study. Lancet, 2016 published online Dec 6. http://dx.doi.org/10.1016/S0140-6736(16)31408-8.
3. 3 Mercuri, E, Bertini, E, Iannaccone, ST, Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 11 (2012), 443–452.
4. 4 Lorson, CL, Hahnen, E, Androphy, EJ, Wirth, B, A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96 (1999), 6307–6311.
5. 5 Hua, Y, Vickers, TA, Okunola, HL, Bennett, CF, Krainer, AR, Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82 (2008), 834–848.
6. 6 Passini, MA, Bu, J, Richards, AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med, 3, 2011, 72ra18.
7. 7 Chiriboga, CA, Swoboda, KJ, Darras, BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86 (2016), 890–897.
8. 8 Kariya, S, Obis, T, Garone, C, et al. Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest 124 (2014), 785–800.
9. 9 Hamilton, G, Gillingwater, TH, Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19 (2013), 40–50.
10. 10 Hua, Y, Sahashi, K, Rigo, F, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478 (2011), 123–126.
11. 11 Hosseinibarkooie, S, Peters, M, Torres-Benito, L, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet 99 (2016), 647–665.
12. 12 Wishart, TM, Mutsaers, CA, Riessland, M, et al. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Invest 124 (2014), 1821–1834.